NR3C2 and malignant hypertension: A DRI can efficiently suppress the AT1R by inhibiting compensatory activation of renin, while an MRA can decrease BP by inhibiting both aldosterone-dependent and aldosterone-independent activation of the MR in patients with MHT (Fig. 5).